Aged 18 to 80 years old (including threshold), regardless of gender;
There is a history of novel coronavirus antigen- or nucleic acid-positive infection within 1 week;
HRCT is consistent with the manifestation of viral pneumonia (judged by the investigator)
Participants who voluntarily sign informed consent.
You may not be if
Participants who cannot take orally, or are suspected to be allergic to Jaktinib hydrochloride, similar drugs or their excipients, or have severe gastrointestinal dysfunction that affects drug absorption;
Critical pneumonia patients with other organ failure requiring ICU monitoring and treatment;
Participants who have received the following treatments within the specified time window before randomization:
1. participants have received Janus kinase (JAK) inhibitor, interleukin 6 (IL-6) inhibitor, IL-1 inhibitor, tumor necrosis factor (TNF) inhibitor, T cell or B cell depletion agent, interferon and other immunosuppressive drugs within the first two weeks of randomization, except glucocorticoid;
2. Systematically used CYP 3A4 potent inhibitor or potent inducer in the first five drug half lives at random;
Immune deficiency;
Participants who have received novel coronavirus vaccine within 1 week before randomization;
Prior to randomization, there were the following active and uncontrolled infections: tuberculosis, HIV, syphilis, mycoplasma, chlamydia, parasites, and viral infections other than SARS CoV-2 that required systemic anti-infection treatment;
Renal diseases requiring dialysis treatment;
Pregnant and lactating women;
Any other participants that were considered unsuitable by the investigator.
